Valutazione dei costi della profilassi di un episodio di nausea e vomito indotto da chemioterapia: palonosetron versus 5-HT3 inibitori di prima generazione-Reference-Cited by-同舟云学术

Valutazione dei costi della profilassi di un episodio di nausea e vomito indotto da chemioterapia: palonosetron versus 5-HT3 inibitori di prima generazione

Published:2007-01 Issue:1 Volume:9 Page:21-30
ISSN:1590-9158
Container-title:PharmacoEconomics Italian Research Articles
language:it
Short-container-title:Pharmacoeconomics-Ital-Res-Articles

Author:

Ravasio Roberto,Luciani C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy

Link

http://link.springer.com/content/pdf/10.1007/BF03320567.pdf

Reference25 articles.

1. Bender CM, McDaniel RW, Murphy-Ende K, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 2002; 6(2): 94–102

2. Gralla R. Antiemetic Therapy. In: Bast R, Kufe D, Pollock R, et al., editors. Cancer Medicine (online version). Hamilton, Ontario: BC Decker, 2000

3. Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002; 10(7): 519 22

4. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999; 56(8): 729 64

5. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17(9): 2971 94

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-consequence analysis of aprepitant compared to standard therapy (5-HT 3 + corticosteroids) for the prevention of highly emetogenic chemotherapy-induced nausea and vomit;Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish;2015-05

2. Palonosetron;Drugs;2009-11

3. Analisi di costo-efficacia di pemetrexed più cisplatino versus gemcitabina più cisplatino nel trattamento di prima linea in pazienti con NSCLC non squamoso in stadio avanzato;Giornale Italiano di Health Technology Assessment;2009-06